Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 263

1.

Oncolytic herpes simplex virus therapy for peripheral nerve tumors.

Jeyaretna DS, Rabkin SD, Martuza RL.

Neurosurg Focus. 2007 Jun 15;22(6):E4. Review.

PMID:
17613221
2.

Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.

Berto E, Bozac A, Volpi I, Lanzoni I, Vasquez F, Melara N, Manservigi R, Marconi P.

Cancer Gene Ther. 2007 Sep;14(9):791-801. Epub 2007 Jun 8.

PMID:
17557110
4.
5.

Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.

Hoffmann D, Wildner O.

Cancer Gene Ther. 2007 Jul;14(7):627-39. Epub 2007 May 4.

PMID:
17479104
6.

Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene.

Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, Li H, Himmelreich U, Lange C, Stenzel W, Deckert M, Neumann H, Jacobs AH, von Laer D.

Mol Ther. 2007 Jul;15(7):1373-81. Epub 2007 Apr 24.

7.

An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas.

Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA, Wang GY, Miao LV, Huynh H, Hui KM.

Mol Ther. 2007 Jun;15(6):1129-36. Epub 2007 Apr 10.

8.
10.

Imaging-guided gene therapy of experimental gliomas.

Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, Heneka MT, Herrlinger U, Fraefel C, Graf R, Wienhard K, Heiss WD.

Cancer Res. 2007 Feb 15;67(4):1706-15.

11.

[Herpes simplex virus vaccine studies: from past to present].

Us D.

Mikrobiyol Bul. 2006 Oct;40(4):413-33. Review. Turkish.

PMID:
17205702
12.

Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Sortwell CE, Bowers WJ, Counts SE, Pitzer MR, Fleming MF, McGuire SO, Maguire-Zeiss KA, Federoff HJ, Collier TJ.

Brain Res. 2007 Feb 23;1134(1):33-44. Epub 2006 Dec 28.

13.

Oncolytic HSV-1 for the treatment of brain tumours.

Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ.

Herpes. 2006 Nov;13(3):66-71. Review.

PMID:
17147910
14.

Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.

Sia KC, Wang GY, Ho IA, Khor HY, Miao L, Hui KM, Lam PY.

J Virol Methods. 2007 Feb;139(2):166-74. Epub 2006 Oct 30.

PMID:
17074404
15.

Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.

Sabbioni S, Callegari E, Manservigi M, Argnani R, Corallini A, Negrini M, Manservigi R.

Gene Ther. 2007 Mar;14(5):459-64. Epub 2006 Oct 19.

PMID:
17051250
16.

Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector.

Watanabe D, Brockman MA, Ndung'u T, Mathews L, Lucas WT, Murphy CG, Felber BK, Pavlakis GN, Deluca NA, Knipe DM.

Virology. 2007 Jan 20;357(2):186-98. Epub 2006 Sep 22.

18.

Improved HSV-1 amplicon packaging using virion host shutoff mutants lacking mRNAse activity.

Halterman MW, Giuliano RE, Bowers WJ, Federoff HJ.

J Gene Med. 2006 Nov;8(11):1320-8.

PMID:
16989006
19.

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D, Bronson RT, Lifson JD, Rosati M, Pavlakis GN, Felber BK, Knipe DM, Desrosiers RC.

Virology. 2007 Jan 20;357(2):199-214. Epub 2006 Sep 7.

20.

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses.

Bozac A, Berto E, Vasquez F, Grandi P, Caputo A, Manservigi R, Ensoli B, Marconi P.

Vaccine. 2006 Nov 30;24(49-50):7148-58. Epub 2006 Jul 12.

PMID:
16884834

Supplemental Content

Support Center